Navigation Links
Frost & Sullivan: Momentum Mounting for Catheter Ablation Technologies in Treatment of Atrial Fibrillation
Date:6/8/2009

Clinical Specialists Provide Feedback on Current and Future Trends

MOUNTAIN VIEW, Calif., June 8 /PRNewswire/ -- A recent Frost & Sullivan end-user survey shows increased awareness and utilization of new tools and approaches to treating atrial fibrillation (Afib). Of the various forms of cardiac arrhythmia, AFib is the one of the most prevalent and hardest to treat. Two and a half million people in the U.S. have AFib, and about one million are symptomatic and do not respond well to traditional drug therapy and behavior modification (diet, exercise). Approximately 200,000 new cases of AFib are diagnosed annually in the U.S. While medical device therapy options are increasing, their adoption and utilization for atrial fibrillation has been slow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Market estimates show that less than 20 percent of the addressable market for atrial fibrillation therapy is being served due to limited regulatory approval and lack of provider training and expertise. The market that participants like to call "two years away, for the past ten years," is now building momentum due to ongoing clinical research and recent FDA approval of the first catheter ablation system for treatment of atrial fibrillation in February of 2009.

The latest end-user study from Frost & Sullivan's Medical Device group assesses a variety of critical dynamics of catheter ablation approaches and technologies in treatment of both paroxysmal and long-standing persistent atrial fibrillation. Electrophysiologists, cardiologists, and cardiac surgeons provided insight on factors such as adoption drivers, clinical preferences, expected impact of the economy, referral patterns, assistive technologies and brand perceptions.

Select findings include the following:

  • Compared to results collected during Frost & Sullivan's 2007 End User Perceptions of Atrial Fibrillation Study, a statistically significant increase in awareness of the latest trends in EP ablation procedures and technologies was noted.
  • One-quarter of Electrophysiologists currently use robotic-assisted magnetic navigation systems. Of those who do not, 41 percent report that they are very unlikely to adopt a robotic or magnetic system for ablation in the next 12 months.
  • Upgrading of existing products / technologies is foreseen to be very or somewhat negatively impacted by the economy by 53% of responding Electrophysiologists.
  • The most utilized ablation strategy for Paroxysmal Atrial Fibrillation is wide area circumferential ablation. The least utilized ablation strategy is Target Fractionated Electrograms.
  • Cardiologists on average estimate that 35 percent of their patients are aware of and receptive to ablation procedures.

Fieldwork for this study was conducted in March of 2009, a total sample was achieved of 166 clinicians, broken out into 103 Electrophysiologists, 47 General Cardiologists, and 16 Cardiac Surgeons within the U.S.

From the Analyst

"The atrial fibrillation market is considered to be one of the next major opportunities for growth in the cardiovascular space, particularly for companies focused on management and treatment of cardiac rhythm disorders," notes Frost & Sullivan Industry Manager Venkat Rajan. "Due to mounting clinical support and the concurrent maturation of assistive technologies that enable for more accurate target identification and treatment planning, the market is poised to undergo a significant change over the next five years."

"As the market continues to develop, there are number of key clinical and product features that system developers must define themselves around as they seek distinction in the marketplace," explains Rajan.

Link

http://www.medicaldevices.frost.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Johanna Haynes
    Frost & Sullivan
    +1.210.247.3870
    johanna.haynes@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frost & Sullivan Presents LG Electronics IRIS With the 2009 Global Iris Recognition Biometrics Market Customer Value Leadership of the Year Award
2. IT Budgets of Healthcare Organizations in Asia Pacific Region Expected to Grow, Regardless of the Economic Slowdown, says Frost & Sullivan
3. Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan
4. European Prebiotics Market Diversifies Strongly Across New Application Sectors in Food and Beverage Industry, Finds Frost & Sullivan
5. Frost & Sullivan: Healthcare Delivery in APAC Upon Economic Recession
6. Frost & Sullivan Looks at the Influence of Chinas New Health Reform on the Pharmaceutical Market
7. Frost & Sullivan: SMBG Within Asia Pacific
8. Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan
9. Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
10. Frost & Sullivan Cites Gearworks for Creativity and Customer Service in the Home Healthcare Market
11. Focus on Rapid Medical Response to Improve the Quality of Healthcare and Drive the Ambulance Services Market in Europe, According to Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services ... Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. ... will facilitate the development of a hub and spoke model for opioid treatment ...
(Date:7/24/2017)... ... July 24, 2017 , ... Peruvian Ayahuasca retreat, ... be awarded annually to and divided between two full-time university students enrolled in ... Amazonian plant medicine. To apply for the scholarship, students are asked to submit ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider ... partnered with WALLIX to expand its solution to help government contractors more ... a number of ways to address the authentication requirements within NIST SP800-171, but ...
(Date:7/24/2017)... ... 24, 2017 , ... A CDC study shows that, although people are taking more steps to ... 29), had at least one case of sunburn within the past year. It’s common and ... ignore the issue. However, only recently have people become conscientious of the risks that accompany ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
Breaking Medicine Technology: